On January 7, 2020 Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, reported that preliminary data from the company’s Phase 1 clinical trial (RMC-4630-01) of RMC-4630 will be presented at the 6th AACR (Free AACR Whitepaper)-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic being held January 11-14, 2020 in San Diego, CA (Press release, Revolution Medicines, JAN 7, 2020, https://www.prnewswire.com/news-releases/revolution-medicines-to-present-preliminary-data-from-phase-1-clinical-trial-of-rmc-4630-at-6th-aacr-iaslc-international-joint-conference-300982012.html [SID1234552825]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
RMC-4630, the company’s investigational SHP2 inhibitor, is a potent and orally bioavailable small molecule that is designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a key role in modulating cell growth by transmitting signals from receptor tyrosine kinases to RAS. The ongoing Phase 1 monotherapy study is evaluating RMC-4630 for a range of tumor types featuring specific, molecularly-defined oncogenic mutations.
Data from the study will be reported in podium and poster presentations entitled, "The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial."
Details of the presentations are as follows:
Podium Presentation:
Session: Plenary Session 1: Therapeutic Targeting and Vulnerabilities of Ras-Driven Lung Cancer
Presenting Author: Sai-Hong Ignatius Ou, M.D., Ph.D., Chao Family Comprehensive Cancer Center, University of California, Irvine
Session Date/Time: Saturday, January 11, 2020, 4:30 – 6:15 p.m. Pacific
Poster Presentation:
Poster Number: A12
Session: Poster Session A
Presenting Author: Sai-Hong Ignatius Ou, M.D., Ph.D., Chao Family Comprehensive Cancer Center, University of California, Irvine
Session Date/Time: Sunday, January 12, 2020, 12:00 – 2:00 p.m. Pacific
In addition to the presentations on RMC-4630, Revolution Medicines will also report preclinical data on its mutant RAS(ON) inhibitors in a poster presentation at the conference. Details of that presentation are as follows:
Poster Presentation:
Poster Number: A06
Title: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC
Session: Poster Session A
Presenting Author: Robert Nichols, Ph.D., associate director, systems biology at Revolution Medicines
Session Date/Time: Sunday, January 12, 2020, 12:00 – 2:00 p.m. Pacific
About RMC-4630 and Sanofi Collaboration
The RMC-4630 program is the focus of an exclusive global research, development and commercialization agreement with Sanofi, under which Revolution Medicines received a $50 million upfront payment, and Sanofi agreed to reimburse Revolution Medicines for substantially all research and all development costs for the joint SHP2 program. Sanofi received an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote right for Revolution Medicines. The companies have agreed to enter into a 50/50 profit and loss share arrangement in the U.S., and Revolution Medicines is entitled to receive tiered royalties on annual net sales ranging from high single digit to mid-teen percentages on sales in other markets. Revolution Medicines could also receive more than $500 million in development and regulatory milestone payments.